DRDO invites EoI to transfer technology of 2-DG drug for bulk production
The Hindu
The 2-DG was developed by the Institute of Nuclear Medicine and Allied Sciences, a lab of DRDO, in collaboration with Dr. Reddy’s Laboratories.
The Defence Research and Development Organisation (DRDO), which developed 2-Deoxy-D- Glucose (2-DG), a drug used for treatment of COVID-19 patients, has called for Expression of Interest (EoI) to transfer the technology to Indian pharmaceutical industries for production. The 2-DG was developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in collaboration with . Clinical trial results have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence.More Related News